SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cell Therapeutics (CTIC)
CTIC 9.0900.0%Jun 26 5:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (262)7/29/2004 1:39:59 PM
From: Icebrg  Read Replies (2) of 946
 
Well, what can a poor company do? Apart from having the CEO travelling around in leased company jet?

For the time being there is not much interest from CTIC in solid tumors as far as Trisenox is concerned. In the recent prospectus
they said the following: We have recently refocused our TRISENOX development efforts to approximately 40 clinical and
investigator-sponsored trials, with an emphasis on blood-related cancers, including front-line APL and multiple myeloma.
This is also confirmed in the specification of currently run Trisenox trials. It is still an impressive number of trials that are ongoing.
They seem to want to try everything. Sorry, for the messy lay-out.

Erik


TRISENOX 	   	 
Multiple Myeloma (MM) 	   	 

•        Single agent (two trials)
	   	II / enrollment completed

•        Single agent, twice weekly dosing schedule
	   	II / enrollment completed

•        Combination with ascorbic acid and dexamethasone following high dose chemotherapy 
and autologous stem cell transplant*
	   	II / open

•        Combination with thalidomide in refractory MM*
	   	II / open

•        Combination with ascorbic acid prior to high dose chemotherapy
 
with autologous stem cell rescue for stage II/III MM*
	   	II / open

•        Combination with dexamethasone after stem cell transplant*
	   	II / open

•        Combination with melphalan and ascorbic acid in relapsed/refractory MM*
	   	II / open

•        Combination with ascorbic acid and dexamethasone*
	   	II / open
	
Myelodysplastic Syndromes (MDS) 	   	 

•        Single agent (2 trials)
	   	II / enrollment completed

•        Single agent, followed by combination with thalidomide for non-responders*
	   	II / open

•        Single agent (5 trials)*
	   	I/II / open

•        Combination with cytarabine*
	   	I/II / open

•        Combination with Ara-C*
	   	I/II / open

•        Combination with amifostine*
	   	II / open
	

Acute Promyelocytic Leukemia (APL)
	   	 

•        Single agent, APL in molecular relapse*
	   	II / open

•        Combination with ATRA, de novo APL*
	   	II / open

•        Consolidation for primary treatment of APL*
	   	II / open
	
Other Leukemia/Lymphoma 	   	 

•        Comination with Gleevec for CML (3 trials)*
	   	I/II / open

•        Combination with ascorbic acid for non-APL AML*
	   	II / open

•        Combination with ascorbic acid for relapsed/refractory lymphoid malignancies*
	   	II / open

•        Single agent in cutaneous T-cell lymphoma*
	   	II / open
	
Solid Tumors 	   	 

•        Single agent for neuroblastoma solid tumors in pediatric patients*
	   	II / open

•        Combination with radiosurgery/radiotherapy for malignant glioma (2 trials)*
	   	I/II / open
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News